<DOC>
	<DOCNO>NCT00463242</DOCNO>
	<brief_summary>This study evaluate efficacy , safety tolerability agomelatine 25 mg 50 mg per day compare agomelatine paroxetine tolerability . Eligible patient receive double-blind study medication 8 week . One week completion double-blind treatment phase single follow-up visit .</brief_summary>
	<brief_title>A Placebo- Paroxetine-controlled Study Efficacy , Safety Tolerability Agomelatine ( 25 50 mg ) Treatment Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Paroxetine</mesh_term>
	<mesh_term>S 20098</mesh_term>
	<criteria>Male female adult , 18 70 year age , inclusive Diagnosis Major Depressive Disorder accord DSMIV criterion HAMD17 total score &gt; = 22 Screening Baseline History nonresponse paroxetine Patients previously treat agomelatine History bipolar disorder ( I II ) , schizophrenia , schizoaffective disorder , eat disorder , obsessive compulsive disorder Any current Axis I disorder major depressive disorder focus treatment Substance alcohol abuse last 30 day , dependence last 6 month Use psychoactive medication screen visit Female patient childbearing potential use effective contraception Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>agomelatine , Major Depressive Disorder , MDD , depression</keyword>
</DOC>